Yves Allory is an expert in Urology at Institut Curie (France). As of October 2026, ScienceLeadR ranks Yves Allory in the top 1% of experts worldwide for Urinary Bladder Diseases, Urologic Neoplasms and Urogenital Neoplasms. Yves Allory has authored 399 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,055 (community average: 125). How the SLR is computed.

LeadR Profile

Yves Allory Institut Curie France
1 055 ScienceLeadR Reputation 1055
Network Map

Urology

Subspecialties: Oncology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026

Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 399

Citations

Citations: 14 447 1st author: 16 Last author: 30 Unique author: 13


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database.
PMID 42740896 — urinary bladder, urinary bladder neoplasms, financial stress, muscles, neoplasms, diagnosis, therapeutics, non-muscle invasive bladder neoplasms, snds
Eur Urol Open Sci20260
FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.
PMID 42544574 — urinary bladder, urinary bladder neoplasms, cells, genes, gene regulatory networks, neoplasms, genes, regulator, cell line
J Clin Invest20260
Corrigendum to "Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis" The Lancet Regional Health - Europe, Volume 60, January 2026, 101524.
PMID 42529191 — neoplasms
Lancet Reg Health Eur20260
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.
PMID 42448514 — research design, polymerase chain reaction, urologic neoplasms, diagnosis, therapeutics
Eur Urol Oncol20260
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
PMID 42420157 — urinary bladder, urinary bladder neoplasms, genes, muscles, clinical decision-making, neoplasms, chromatin, decision making, biomarkers, therapeutics, mutation, non-muscle invasive bladder neoplasms
Eur Urol Oncol20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 1

By phase:

N/A 3
Phase 2 1
Phase 3 1

By status:

Completed 3
Active not recruiting 1
Unknown 1

By type:

Interventional 3
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 1
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
NCT06294054 — urinary bladder, urinary bladder neoplasms, intelligence, muscles, blood, neoplasms, drug therapy, cystectomy, genomic instability, artificial intelligence, chemotherapy
N/AActive not recruiting2023

LeadR Networks

Main global connection map